The first copper(I) complex of tris(hydroxymethyl)phosphine

Bharathi, D. Saravana; Sridhar, M. A.; Prasad, J. Shashidhara; Samuelson, Ashoka G.

doi:10.1016/s1387-7003(01)00253-2

Cited by 18 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the complex {[HC(CO 2 ) (pz Me2 ) 2 ]Cu(thp) 2 } (63) was found to possess antiproliferative activity against different human tumor cell lines (HL60, A549, MCF-7, A375 and LoVo) markedly higher than that shown by cisplatin. Physico-chemical characterization indicated that they possessed a tetrahedral geometry both in the solid state [233] and in the solution state [147]. Flow cytometry analysis on 2008 human ovarian carcinoma cells showed that (63) induced a marked enlarge of both cell size and granularity and a significant increase in the fraction of G2/M cells that was not accompanied by the appearance of a relevant sub-G1 fraction.…”

Section: Phosphine Complexesmentioning

confidence: 99%

Copper Complexes as Anticancer Agents

Marzano

Pellei²,

Tisato³

et al. 2009

ACAMC

732

395

View full text Add to dashboard Cite

Metal-based antitumor drugs play a relevant role in antiblastic chemotherapy. Cisplatin is regarded as one of the most effective drugs, even if severe toxicities and drug resistance phenomena limit its clinical use. Therefore, in recent years there has been a rapid expansion in research and development of novel metal-based anticancer drugs to improve clinical effectiveness, to reduce general toxicity and to broaden the spectrum of activity. The variety of metal ion functions in biology has stimulated the development of new metallodrugs other than Pt drugs with the aim to obtain compounds acting via alternative mechanisms of action. Among non-Pt compounds, copper complexes are potentially attractive as anticancer agents. Actually, since many years a lot of researches have actively investigated copper compounds based on the assumption proposal that endogenous metals may be less toxic. It has been established that the properties of copper-coordinated compounds are largely determined by the nature of ligands and donor atoms bound to the metal ion. In this review, the most remarkable achievements in the design and development of copper(I, II) complexes as antitumor agents are discussed. Special emphasis has been focused on the identification of structure-activity relationships for the different classes of copper(I,II) complexes. This work was motivated by the observation that no comprehensive surveys of copper complexes as anticancer agents were available in the literature. Moreover, up to now, despite the enormous efforts in synthesizing different classes of copper complexes, very few data concerning the molecular basis of the mechanisms underlying their antitumor activity are available. This overview, collecting the most significant strategies adopted in the last ten years to design promising anticancer copper(I,II) compounds, would be a help to the researchers working in this field.

show abstract

Section: Phosphine Complexesmentioning

confidence: 99%

Copper Complexes as Anticancer Agents

Marzano

Pellei²,

Tisato³

et al. 2009

ACAMC

732

395

View full text Add to dashboard Cite

show abstract

tris(hydroxymethyl)phosphine

Crosby¹

2020

Catalysis From a to Z

View full text Add to dashboard Cite

The First Copper Complexes Bearing the 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) Ligand

Kirillov¹,

Smoleński²,

Silva³

et al. 2007

Eur J Inorg Chem

View full text Add to dashboard Cite

The CuI compound [Cu(PTAH)4](NO3)5 (1) {PTAH = N‐protonated form of 1,3,5‐triaza‐7‐phosphaadamantane (PTA)} was easily prepared by reacting hydrated Cu(NO3)2 and PTA in aqueous acidic solution at room temperature. Further treatment of 1 with sodium hydroxide in water led to an unprotonated PTA derivative [Cu(PTA)4](NO3) (2). Both compounds are water‐soluble and air‐stable, and were characterized by IR, 1H‐, 13C{1H}‐, 31P{1H}‐ and 63Cu NMR spectroscopy, FAB‐MS(+), elemental and single‐crystal X‐ray diffraction structural analyses. They exhibit a nearly regular tetrahedral coordination environment about each copper centre filled by the phosphorus atoms of the four PTAH/PTA moieties, which show distinct and unusual geometrical arrangements if viewed along the P–Cu bonds. The 31P{1H}‐ and 63Cu NMR spectra of 2 in D2O solution show spin coupling between the 31P and 63Cu nuclei at room temperature. These compounds represent the first examples of Cu complexes bearing PTA or any derived ligand with a cagelike PTA core and expand the restricted family of aqua‐soluble copper phosphane complexes. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)

show abstract

The first copper(I) complex of tris(hydroxymethyl)phosphine

Cited by 18 publications

References 18 publications

Copper Complexes as Anticancer Agents

Copper Complexes as Anticancer Agents

tris(hydroxymethyl)phosphine

The First Copper Complexes Bearing the 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) Ligand

Contact Info

Product

Resources

About